The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma

This publication has 44 references indexed in Scilit:

• Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy
  Cancer Gene Therapy, 2000
• Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi‐mutated herpes simplex virus type‐1 (G207)
  The FASEB Journal, 1999
• Treatment of Human Breast Cancer in a Brain Metastatic Model by G207, a Replication-Competent Multimutated Herpes Simplex Virus 1
  Human Gene Therapy, 1998
• Molecular Mechanisms of Interferon Resistance Mediated by Viral-Directed Inhibition of PKR, the Interferon-Induced Protein Kinase
  Pharmacology & Therapeutics, 1998
• Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
  Nature Medicine, 1995
• Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.
  Proceedings of the National Academy of Sciences, 1995
• The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells.
  Proceedings of the National Academy of Sciences, 1992
• The Pathogenicity of Ribonucleotide Reductase-Null Mutants of Herpes Simplex Virus Type 1 in Mice
  The Journal of Infectious Diseases, 1991
• Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
  Science, 1991
• Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant
  Virology, 1988